Progeria: a perspective on potential drug targets and treatment strategies

EXPERT OPINION ON THERAPEUTIC TARGETS

Volume 26, Issue 5, Pages 393-399

TAYLOR & FRANCIS LTD

Hutchinson-Gilford progeria syndrome; farnesyltransferase (FTase); isoprenylcysteine carboxyl methyltransferase (ICMT); antisense oligonucleotide (ASO); gene editing; CRISPR/Cas9; adenine base editor (ABE)

Pharmacology & Pharmacy

1. Spanish Ministerio de Ciencia e Innovacion (MCIN)/Agencia Estatal de Investigacion (AEI) [PID2019-108489RB-I00]
2. European Regional Development Fund ('A way to build Europe')
3. Fundacio la Marato TV3 [202033]
4. Progeria Research Foundation (PRF) [PRF 2019-77]
5. Asociacion Progeria Alexandra Peraut
6. PRF
7. Swedish Research Council
8. Comunidad Autonoma de Madrid [2017-T1/BMD5247]
9. Instituto de Salud Carlos III
10. Pro-CNIC Foundation
11. MCIN/AEI [CEX2020-001041-S]
12. Center for Innovative Medicine